Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data

ExpExpert Opin Drug Saf. 2023;22(12):1317–1320 doi: 10.1080/14740338.2023.2248872

This study presents initial data suggesting an association between the use of JAK inhibitors and pemphigus. This research used the FAERS database to investigate connections between JAK inhibitor usage and the occurrence of pemphigus as an adverse event.

The authors found that females, individuals aged 40–49 and RA patients were more susceptible to pemphigus than other demographics, perhaps due to the immunopathogenesis. Higher rates of pemphigus were also observed in patients receiving tofacitinib compared with upadacitinib.